.svg){kind=logo}
Exclusivity Engineered: AI-Driven eLearning Solutions for Retail & Luxury
Gain efficiency while maintaining human artistry with a hybrid AI-human approach.
Case Study: Multilingual Retail Marketing
New AI Content Creation Solutions for a Sports and Apparel Giant
- RESOURCES
In today’s multi-regional clinical trial landscape, sponsors face increasing pressure to accelerate timelines, navigate complex regulatory requirements, and deliver patient-relevant study results worldwide. However, fragmented workflows and inconsistent labeling processes can slow progress and delay trial outcomes.
During our webinar, “Mature Clinical Labeling Models and Language Excellence,” Pharma consultant Martin Koenig and Lionbridge experts Mayowa Ojeyomi and Pia Windelov discussed how strategic clinical labeling and language excellence help sponsors overcome common challenges and reach operational excellence.
Want to watch the webinar in its entirety? Click the button below to access the on-demand recording.
What Challenges Are Trial Sponsors Facing in Clinical Labeling?
Clinical labeling is a pivotal step for successful study start-up since no trial can begin recruiting patients until the study drug is ready on site with correct, country-specific, compliant labeling.
Clinical labeling regulations are complex and dynamic, and sponsors face regulatory pressure to accelerate clinical trial execution. Initiatives such as the Accelerating Clinical Trials in the EU (ACT EU) aim to shorten trial authorization procedures and trial start-up. However, only about half of the trials currently executed in the EU start patient recruitment within the targeted 200 days from clinical trial submission. Many sponsors struggle to accelerate on-site trial initiation due to fragmented workflows, inefficient labeling, and unclear internal alignment, all of which can lead to delays.
The root of these challenges often lies in disconnected processes and lengthy, complex Standard Operating Procedures (SOPs). Different teams and subgroups may work in silos, making it difficult to ensure consistency and accountability across clinical labeling operations. Without efficient workflows and proper governance, sponsors face risks of errors and inefficient execution, which can ultimately threaten trial timelines.
To address these challenges and accelerate clinical trial labeling, sponsors should focus on minimizing rework cycles from the outset.
How Can You Minimize Labeling Delays?
Avoidable rework cycles lead to labeling delays. The opportunity lies in reducing cycles at the source and during execution, rather than rushing at the end of the cycle.
Here’s how:
- Ensure structured inputs during kickoffs to prevent clarification loops later.
- Provide a consistent source of Master English Label Text (MELT) to prevent reconciliation and approval churn.
- Manage country-specific changes at the source to prevent divergence and reduce rework during execution.
What Are Mature Clinical Labeling Models?
Mature clinical labeling models aim to address the underlying causes of delays and inefficiencies in clinical trial labeling.
Instead of focusing solely on speed, these models emphasize reducing avoidable rework cycles early and during implementation. They incorporate clear governance, strong language assets, integrated quality checks, and standardized procedures to ensure complete and consistent inputs from the start.
With curated Translation Memories (TMs), validated phrase libraries, and full traceability, mature models streamline labeling from initial intake through regulatory validation, translation, and quality assurance, enabling scalable, repeatable execution across the clinical lifecycle.
How Do Mature Clinical Labeling Models Reduce Friction Across Teams and Updates?
Mature clinical labeling models reduce friction by applying three key principles: Ownership clarity, language consistency, and controlled change execution.
- Clear decision-making and defined ownership prevent approvals from stalling and ensure accountability across regulatory, clinical supply, and artwork teams.
- Consistent terminology and intent, from Master English Label Text (MELT) to country-specific versions, minimize reconciliation work and repeated approvals.
- Controlled change execution means updates are handled through impact-driven decisions, avoiding unnecessary rework.
When these principles are applied consistently, it leads to fewer decisions, fewer cycles, and more predictable timelines for clinical labeling operations.
What Defines a Mature Clinical Labeling Model and How Does It Speed up Global Trial Success?
Four core elements define a mature clinical labeling model:
- Governance
- Reuse
- Quality
- Standardization
These interconnected pillars are essential for overcoming operational challenges, driving faster, more predictable timelines, and ensuring regulatory compliance across global markets.
Governance: Clear ownership and decision control
Robust governance ensures that responsibilities are clearly defined and that decision-making authority is established across regulatory, clinical supply, and artwork teams. This clarity prevents approvals from stalling and supports accountability, both of which are critical for keeping workflows moving efficiently and minimizing bottlenecks.
Reuse: Leveraging curated language assets
Mature models use curated Translation Memories (TMs), validated phrase libraries, and consistent terminology and intent from Master English Label Text (MELT) through to country-specific versions. By applying approved phrasing across updates, sponsors reduce reconciliation efforts, avoid repeated approvals, and uphold language quality throughout the clinical lifecycle.
Quality: Integrated checks and SME review
Integrated quality checks, combined with Subject Matter Expert (SME) review, are embedded at every stage. This approach ensures that both regulatory requirements and translated content align before finalization, helping identify deviations early and supporting compliance.
Standardization: Scalable, repeatable execution
Standardized processes and governance of language assets enable scalable, repeatable execution. Complete and consistent inputs are captured upfront, reducing clarification loops and supporting traceability throughout the workflow. Regulatory validation, translation, and quality assurance are handled as a continuous, connected process rather than fragmented activities across teams or vendors.
When these four elements are consistently applied, mature clinical labeling models reduce friction, avoidable rework, and approval churn, enabling sponsors to accelerate global trial success and deliver patient-ready drugs efficiently.
Why Is Language Excellence Essential for Clinical Labeling?
Language excellence ensures that clinical labeling content is consistent, accurate, and compliant across global markets. Applying it strategically enables you to move faster.
Leverage language excellence by:
- Using centralized Translation Memories (TMs) to achieve labeling that supports regulatory requirements and minimizes rework.
- Embedding language assets into workflows, from early development through commercialization, to enable scalable operations, reduce delays, and drive Return on Investment (ROI).
“We see firsthand how impactful language excellence is in clinical trial execution, drug development, and end-to-end labeling. We see many customers missing out on opportunities to drive efficiencies and language consistency because they do not think strategically about language.”
—Pia Windelov, Lionbridge Vice President, Life Sciences Strategy and Product Marketing
Why Partner With Lionbridge for Clinical Trial Label Services?
With over 20 years of experience delivering language and labeling solutions to the pharma industry, Lionbridge’s services support the entire clinical, regulatory, and commercial lifecycle — from initial clinical trial preparation and application through trial execution and reporting, to regulatory filing and both Investigational Medicinal Product (IMP) and commercial labeling.
Our clinical trial labeling services are different
Unlike many traditional labeling service providers, Lionbridge sets itself apart by being deeply rooted in both technology and language.
We integrate regulatory validation, translation, and quality assurance into a single, efficient workflow, supported by technology and deep language expertise. Lionbridge’s approach addresses common challenges such as fragmented workflows, unclear ownership, and avoidable rework cycles, enabling sponsors to accelerate timelines and reliably meet ambitious recruitment and regulatory goals.
We offer a continuously updated phrase library
A key feature of Lionbridge’s mature model is the embedded, continuously governed phrase library/database for each client, powered by Lionbridge Aurora AI Clinical Labeling™.
Unlike static or rule-based libraries that require manual maintenance, risk becoming outdated, or fail to account for differences in study information, Aurora AI Clinical Labeling is built for validation. Our process ensures agility, consistency, and accuracy for every label.
You’ll get the results you need
Through our Aurora AI Clinical Labeling infrastructure, regulatory validation, translation, and quality checks are embedded in a single continuous workflow. This integrated approach reduces handoffs and clarification loops while maintaining consistency. It enables scalable, repeatable execution and helps sponsors minimize risk, avoid delays, and expand clinical trials globally with confidence.
What Are the Key Webinar Takeaways?
This webinar explored how mature clinical labeling models and language excellence empower clinical trial sponsors to streamline operations, accelerate timelines, and achieve global regulatory compliance. Here are the key points:
Mature clinical labeling models clarify ownership and responsibilities, reducing errors and delays.
Standardized processes and workflows minimize fragmentation, enabling more efficient labeling execution.
Language excellence ensures consistent and accurate labeling across multiple countries and regions.
Optimized workflows reduce avoidable rework and support faster regulatory validation and quality assurance.
Building and maintaining language assets enables scalable and compliant labeling content throughout the drug lifecycle.
Leveraging technology allows for reproducible, automated processes that support global clinical trial expansion.
Accelerated trial execution is possible when sponsors align labeling operations with regulatory expectations, such as those outlined in the ACT EU.
A mature approach to labeling helps sponsors meet ambitious recruitment timelines and regulatory goals more reliably.
Lionbridge enables sponsors to scale trials globally with agile, governed regulatory validation and integrated workflows, delivering consistent, compliant labeling without extra administrative burden or cost.
Your Top Clinical Labeling and Language Excellence Questions Answered
A: Using multiple vendors across different clinical studies in the same program can create inefficiencies and misalignment, leading to fragmented workflows and inconsistent language outcomes. This approach increases administrative burden and the risk of errors, making it harder to achieve language excellence. A vendor consolidation strategy helps streamline processes and drive consistency throughout the program.
A: Selecting a labeling partner as early as possible during the trial planning stage, and ideally early in the clinical development program, is crucial. Waiting too long can result in stretched timelines, increased potential for mistakes, and last-minute scrambling for solutions. Early partnership allows for proactive planning, reduces mistakes, and helps avoid costly corrective actions that can add weeks to your timeline.
A: Effective change management and review require clear decision-making and ownership, as well as alignment among all stakeholders. Maintain ongoing collaboration with your partner rather than seeking them out as a last resort. This approach ensures clarity, reduces last-minute changes, and streamlines the review and approval process.
A: Lionbridge provides sponsors with a continuously governed and validated phrase library, embedded directly into our workflow. This approach enables seamless reuse of content across studies and countries, ensuring up-to-date, accurate labeling without the administrative burden or extra cost of manual maintenance. As a result, sponsors gain agility and consistency across every study, while our process automatically adapts to evolving requirements and country-specific needs.
A: Proactive planning, early engagement of your partner, and clear governance are essential to avoiding last-minute changes. Mistakes can lead to gaps and corrective actions, which delay study start-up. Forward-looking management and vendor consolidation, rather than a multivendor strategy, help minimize errors and keep timelines on track.
A: Proactive planning is critical because it ensures that all language and labeling requirements are addressed from the start, reducing internal pressure and helping sponsors meet key milestones, such as First Patient In. This approach supports both clinical labeling and other language outcomes, driving overall success and compliance.
A: We’ve supported client explorations of e-labels, and our current model already covers most of what’s required — particularly around controlled updates and compliance. We welcome discussions about your specific requirements.
A: Lionbridge linguists are life sciences qualified and specifically trained (or qualified) in labeling requirements. In addition to translation, Lionbridge has a separate regulatory validation team to ensure country-specific requirements are applied, with both in-house specialists and in-country reviewers maintaining up-to-date standards for over 100 countries (and growing).
A: Yes, Lionbridge employs in-country reviewers and native-speaking SMEs. Default glossaries include the Medical Dictionary for Regulatory Activities (MedDRA) and the European Directorate for the Quality of Medicines & HealthCare (EDQM). The team ensures the use of up-to-date glossaries for each country. Lionbridge is also open to client-specific glossary requests and aligns with country managers during onboarding.
A: Lionbridge offers an online portal for review and approval, connecting in-country reviewers to specific tasks. The portal enables segment-by-segment review, comment, and change tracking. Governance and partnership are key to defining reviewer scope, with data collected periodically to assess and align on necessary changes.
If you’re interested in exploring other Lionbridge webinar topics, visit the Lionbridge webinars page for a library of recordings.
Get in touch
Ready to streamline your clinical labeling operations for faster, scalable, and more predictable study start-up? Reach out today to learn more about our clinical labeling services, clinical trials translation services, and, more broadly, our life sciences translation services.
